大理藥業(603963.SH):參麥注射液未中選省際聯盟集中帶量採購
格隆匯12月23日丨大理藥業(603963.SH)公佈,公司近期參與了中成藥省際聯盟集採領導小組辦公室組織的中成藥省際聯盟集中帶量採購報價,根據中成藥省際聯盟集採領導小組辦公室發佈的《中成藥省際聯盟集中帶量採購擬中選結果公示》,公司產品參麥注射液未中選本次省際聯盟集中帶量採購。
參麥注射液功能主治:參麥注射液屬於心血管疾病用藥,主要用於治療氣陰兩虛型之休克、冠心並病毒性心肌炎、慢性肺心並粒細胞減少症,能提高腫瘤病人的免疫機能,系國家基本藥物目錄品種、國家醫保中成藥甲類產品。
2020年度,參麥注射液銷售額為4317.27萬元,佔公司營業收入的20.21%,其中在鄂、冀、晉、內蒙古、遼、閩、贛、豫、湘、瓊、渝、川、貴、藏、陝、甘、寧、新、新疆兵團(以下簡稱“19省區”)等地區的參麥注射液銷售額約為2480萬元,佔公司營業收入的11.64%;2021年1-9月,參麥注射液銷售額約為1890萬元,佔公司營業收入的14.65%,其中在19省區的參麥注射液銷售額約為1150萬元,佔公司營業收入的8.91%。中成藥省際聯盟集中帶量採購週期為兩年,本次未中選可能會對公司參麥注射液在以上19省區未來兩年的銷售情況造成一定的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.